Innovative Bispecific Nanobody Targeting IL11 and TSLP for Next-Generation Fibrosis Therapy

VHH-P226 is an advanced humanized bispecific nanobody designed to simultaneously target interleukin 11 (IL11) and thymic stromal lymphopoietin (TSLP), two cytokines implicated in the fibrotic process. This novel construct is currently undergoing Biological Testing and demonstrates significant potential as a therapeutic candidate for fibrosis. By addressing both interleukin 11 (IL11) and thymic stromal lymphopoietin (TSLP) pathways, VHH-P226 aims to provide a new treatment avenue for patients affected by fibrosis, a condition with considerable unmet medical needs.

Licensing Opportunity

VHH-P226 is available for external licensing and collaborative partnership. We welcome inquiries from biotech and pharmaceutical companies interested in leveraging this cutting-edge bispecific nanobody platform for fibrosis therapeutics development.

Development Phase

Modality

VHH-P226 is a bispecific antibody construct featuring a single-domain anti-IL11 nanobody fused to the N-termini of both heavy chains of a humanized anti-TSLP IgG. This modular architecture, constructed via a flexible (G4S)2 linker and expressed in Chinese hamster ovary cells, leverages the distinctive advantages of nanobody-based therapies, including compact size, increased stability, and superior tissue penetration. The small molecular format of the nanobody enables better access to fibrotic tissues, where conventional antibodies may be limited by their size. Such properties make VHH-P226 a promising modality for overcoming key therapeutic barriers in fibrosis.

Target

IL11 and TSLP are essential cytokine mediators within the immune system and fibrogenic pathways. IL11 is a pleiotropic signaling molecule involved in inflammatory and fibrotic responses, predominantly expressed in stromal and epithelial cells. TSLP serves as a critical initiator of immune regulation, produced mainly by epithelial cells in tissues susceptible to inflammation and fibrosis. Both IL11 and TSLP are highly relevant in the pathogenesis of fibrosis, as evidence highlights their roles in promoting fibroblast activation and chronic extracellular matrix deposition. Targeting both IL11 and TSLP together offers a strategic advantage—VHH-P226’s dual specificity is designed to downregulate key profibrotic signals within affected tissues, positioning it as a compelling asset for robust anti-fibrotic interventions.

Mechanism of Action

VHH-P226 operates as a dual signal transduction modulator by simultaneously binding and inhibiting IL11 and TSLP activity. Through high-affinity interactions, the bispecific nanobody blocks ligand-receptor engagement, thereby intercepting downstream signaling events that drive inflammation and fibrogenesis. This dual mechanism offers the potential for broader biological impact compared to single-target strategies. Furthermore, the nanobody platform's modular nature allows future development into alternative therapeutic forms such as bispecifics, antibody-drug conjugates, or additional multi-specific constructs to expand clinical utility against fibrosis and related pathologies.

Fibrosis

Fibrosis is a progressive pathological process characterized by excessive deposition of extracellular matrix components, leading to tissue scarring and functional impairment in organs such as the lung, liver, heart, and kidney. Affecting millions globally, fibrosis represents a significant health burden across diverse etiologies, including chronic inflammation, autoimmune diseases, and persistent tissue injury. Current therapeutic strategies encompass immunosuppressants, anti-inflammatory agents, and various forms of targeted therapy. However, these options are often limited by inadequate efficacy, adverse effects, or failure to arrest disease progression. There remains an urgent need for innovative agents that can selectively disrupt key fibrogenic pathways. By targeting IL11 and TSLP, VHH-P226 offers a novel therapeutic mechanism, with the potential to address the root molecular drivers of fibrotic disease and transform patient outcomes where traditional approaches have fallen short.